---
title: "SCGS issues a profit warning, expecting a net loss of 8 million to 16 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/226142848.md"
description: "According to the announcement from SCGS, it is expected that the net profit attributable to the owners of the parent company for the year 2024 will be approximately -8 million to -16 million yuan; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be approximately -5.7 million to -13.7 million yuan"
datetime: "2025-01-24T10:52:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/226142848.md)
  - [en](https://longbridge.com/en/news/226142848.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/226142848.md)
generator: "portal-rs"
---

# SCGS issues a profit warning, expecting a net loss of 8 million to 16 million yuan in 2024

According to the announcement from SCGS (600678.SH), it is expected that the net profit attributable to the owners of the parent company for the year 2024 will be approximately -8 million to -16 million yuan; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be approximately -5.7 million to -13.7 million yuan

### Related Stocks

- [600678.CN](https://longbridge.com/en/quote/600678.CN.md)

## Related News & Research

- [12:38 ETAmerica Will Need Nearly 850,000 More Home Care Workers by 2035 -- 24 Hour Caregivers Says the Race for Caregivers Has Already Begun](https://longbridge.com/en/news/297812541.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [UBL: Premiumization and regulatory reforms fuel strong growth and margin expansion ambitions](https://longbridge.com/en/news/297872232.md)
- [ABN AMRO Corporate Investments says portfolio firms avoid 269,592 tons CO2e in 2025 impact report](https://longbridge.com/en/news/297881828.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**